Cencora, Inc. $COR Shares Sold by Smithbridge Asset Management Inc. DE

Smithbridge Asset Management Inc. DE cut its holdings in Cencora, Inc. (NYSE:COR) by 53.9% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,841 shares of the company’s stock after selling 2,150 shares during the quarter. Smithbridge Asset Management Inc. DE’s holdings in Cencora were worth $578,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of COR. United Bank raised its holdings in shares of Cencora by 4.5% in the 2nd quarter. United Bank now owns 7,032 shares of the company’s stock worth $2,109,000 after purchasing an additional 305 shares in the last quarter. Nebula Research & Development LLC bought a new stake in Cencora during the second quarter worth approximately $595,000. Treasurer of the State of North Carolina grew its position in Cencora by 7.9% in the second quarter. Treasurer of the State of North Carolina now owns 85,534 shares of the company’s stock worth $25,647,000 after buying an additional 6,244 shares during the last quarter. Diversify Advisory Services LLC grew its position in Cencora by 94.1% in the second quarter. Diversify Advisory Services LLC now owns 2,585 shares of the company’s stock worth $747,000 after buying an additional 1,253 shares during the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its holdings in shares of Cencora by 26.0% in the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 73,452 shares of the company’s stock valued at $22,025,000 after buying an additional 15,154 shares in the last quarter. 97.52% of the stock is owned by institutional investors and hedge funds.

Cencora Trading Up 2.8%

NYSE COR opened at $296.43 on Friday. The firm’s 50 day moving average price is $278.14 and its two-hundred day moving average price is $320.54. The company has a debt-to-equity ratio of 3.40, a quick ratio of 0.59 and a current ratio of 0.95. Cencora, Inc. has a twelve month low of $244.82 and a twelve month high of $377.54. The stock has a market cap of $57.67 billion, a price-to-earnings ratio of 22.73, a PEG ratio of 1.60 and a beta of 0.58.

Cencora (NYSE:COR) last released its earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). The business had revenue of $78.36 billion during the quarter, compared to analysts’ expectations of $81.09 billion. Cencora had a net margin of 0.78% and a return on equity of 135.20%. Cencora’s revenue for the quarter was up 3.9% on a year-over-year basis. During the same quarter in the previous year, the company earned $4.42 EPS. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Equities analysts anticipate that Cencora, Inc. will post 17.79 EPS for the current year.

Cencora Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, June 1st. Shareholders of record on Friday, May 15th were given a dividend of $0.60 per share. The ex-dividend date was Friday, May 15th. This represents a $2.40 dividend on an annualized basis and a yield of 0.8%. Cencora’s dividend payout ratio (DPR) is presently 18.40%.

Cencora announced that its board has initiated a share repurchase program on Thursday, May 21st that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the company to repurchase up to 3.9% of its shares through open market purchases. Shares repurchase programs are typically a sign that the company’s board of directors believes its shares are undervalued.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on COR. Evercore set a $360.00 price objective on Cencora in a research report on Wednesday, April 8th. Leerink Partners restated an “outperform” rating on shares of Cencora in a report on Tuesday, March 17th. Robert W. Baird cut their target price on Cencora from $420.00 to $339.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Weiss Ratings lowered Cencora from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday. Finally, Morgan Stanley set a $342.00 price target on Cencora in a research note on Friday, May 8th. Eleven equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, Cencora presently has an average rating of “Moderate Buy” and an average price target of $367.75.

Insider Buying and Selling

In other Cencora news, Director Lauren M. Tyler bought 550 shares of the stock in a transaction on Monday, June 22nd. The shares were bought at an average price of $270.23 per share, with a total value of $148,626.50. Following the purchase, the director directly owned 4,359 shares in the company, valued at $1,177,932.57. The trade was a 14.44% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 0.38% of the company’s stock.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.